Clarion Hotel Sign Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Proteomics and its Application to Translational and Precision Medicine (D3)
Organizer(s) Matthias Mann, Emma K. Lundberg, Albert J.R. Heck and Mathias Uhlén
April 7—11, 2019
Clarion Hotel Sign • Stockholm, Sweden
Discounted Abstract Deadline: Dec 12, 2018
Abstract Deadline: Jan 9, 2019
Scholarship Deadline: Dec 12, 2018
Discounted Registration Deadline: Feb 6, 2019
Organized in collaboration with Knut and Alice Wallenberg Foundation
and Science for Life Laboratory
Sponsored by BioLegend, Inc., Novo Nordisk A/S, Roche and Thermo Fisher Scientific Inc.
and Science for Life Laboratory
Sponsored by BioLegend, Inc., Novo Nordisk A/S, Roche and Thermo Fisher Scientific Inc.
Summary of Meeting:
Proteomics methods have advanced tremendously in just the last few years. Apart from increasingly powerful mass-spectrometric methods, global antibody based methods, chemical biology approaches and genetics/genomics approaches and their combinations are now offering a rich toolbox to study the proteome in many different dimensions. Given this background and the recent completion of in depth proteomes, it is now time to apply proteomics in a more translational context to patient derived primary cells, organoids, xenograft models and indeed to the clinic. MS based proteomics, in particular, interaction proteomics in combination with chemical and structural proteomics, is making crucial contributions to drug development and deeper molecular understanding of disease mechanisms. The analysis of post-translational modifications has become orders of magnitude more comprehensive, quantitative and accessible, now enabling in-vivo and time-resolved studied of a large range of signaling processes. In combination with genome engineering, this opens up entirely new perspectives in precision investigation of deregulated signaling processes in models of oncology, immunology or metabolic diseases. Finally, proteomic profiling of body fluids has matured to a degree that it enables informative ‘phenotyping’ of humans in health and disease, supporting ‘wellness’ and patient stratification/biomarker studies.
View Scholarships/Awards
Proteomics methods have advanced tremendously in just the last few years. Apart from increasingly powerful mass-spectrometric methods, global antibody based methods, chemical biology approaches and genetics/genomics approaches and their combinations are now offering a rich toolbox to study the proteome in many different dimensions. Given this background and the recent completion of in depth proteomes, it is now time to apply proteomics in a more translational context to patient derived primary cells, organoids, xenograft models and indeed to the clinic. MS based proteomics, in particular, interaction proteomics in combination with chemical and structural proteomics, is making crucial contributions to drug development and deeper molecular understanding of disease mechanisms. The analysis of post-translational modifications has become orders of magnitude more comprehensive, quantitative and accessible, now enabling in-vivo and time-resolved studied of a large range of signaling processes. In combination with genome engineering, this opens up entirely new perspectives in precision investigation of deregulated signaling processes in models of oncology, immunology or metabolic diseases. Finally, proteomic profiling of body fluids has matured to a degree that it enables informative ‘phenotyping’ of humans in health and disease, supporting ‘wellness’ and patient stratification/biomarker studies.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
MONDAY, APRIL 8
TUESDAY, APRIL 9
WEDNESDAY, APRIL 10
THURSDAY, APRIL 11
FRIDAY, APRIL 12
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
08:30—09:30
Welcome and Keynote Address
*
Matthias Mann,
Max Planck Institute of Biochemistry, Germany
Madan Babu Mohan,
MRC Laboratory of Molecular Biology, UK
Data Science Approaches to Biological Systems
Data Science Approaches to Biological Systems
09:30—12:00
In Depth Proteomics of Normal and Diseased Tissues
The proteomics tool box for personalized medicine
*
Matthias Mann,
Max Planck Institute of Biochemistry, Germany
Joshua J. Coon,
University of Wisconsin, USA
Comprehensive Tissue Proteomics
Comprehensive Tissue Proteomics
Coffee Break
Emma K. Lundberg,
SciLifeLab Stockholm and School of Biotechnology, KTH, Sweden
Dissecting Spatiotemporal Single Cell Variations of the Human Proteome
Dissecting Spatiotemporal Single Cell Variations of the Human Proteome
Georg Borner,
Max Planck Institute of Biochemistry, Germany
Short Talk: Spatial Proteomics Reveals the Mechanistic Basis of AP-4 Deficiency Syndrome
Short Talk: Spatial Proteomics Reveals the Mechanistic Basis of AP-4 Deficiency Syndrome
Tony Ly,
University of Edinburgh, UK
Short Talk: Proteomic Analysis of Cell State Transitions using PRIMMUS
Short Talk: Proteomic Analysis of Cell State Transitions using PRIMMUS
17:00—19:00
Large-Scale Study of Signaling Pathways
The proteomics tool box for personalized medicine
*
Rudolf H. Aebersold,
Institute of Molecular Systems Biology, ETH Zürich, Switzerland
Giulio Superti-Furga,
Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria
The Human Transportome
The Human Transportome
Jesper V. Olsen,
University of Copenhagen, Denmark
Defining Critical Switches in Cancer Progression by Phospho-Proteomics
Defining Critical Switches in Cancer Progression by Phospho-Proteomics
Bernhard Küster,
Technische Universität München, Germany
The Target Landscape of Clinical Kinase Drugs
The Target Landscape of Clinical Kinase Drugs
Hidetaka Kosako,
Tokushima University, Japan
Short Talk: BioID-Based Screening of Biotinylation Sites Globally Identifies STING Interactors
Short Talk: BioID-Based Screening of Biotinylation Sites Globally Identifies STING Interactors
Paolo Cifani,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: Pathway-Scale Targeted Mass Spectrometry for High-Resolution Functional Profiling of Cell Signaling
Short Talk: Pathway-Scale Targeted Mass Spectrometry for High-Resolution Functional Profiling of Cell Signaling
08:30—11:45
Chemical Proteomics and Drug Discovery
Proteomics networks and drug discovery
*
Ileana M. Cristea,
Princeton University, USA
Alexander Makarov,
Thermo Fisher, Germany
Mass Spectrometry Based Proteomics from Ion’s Perspective
Mass Spectrometry Based Proteomics from Ion’s Perspective
Yasushi Ishihama,
Kyoto University, Japan
Toolbox for Phosphoproteomics in Cancer Signaling
Toolbox for Phosphoproteomics in Cancer Signaling
Coffee Break
Michael B. Yaffe,
Massachusetts Institute of Technology, USA
Proteomics and Cell Signaling
Proteomics and Cell Signaling
Marcus Bantscheff,
GlaxoSmithKline, Germany
Proteomics for Drug Target Discovery
Proteomics for Drug Target Discovery
Jing Yang,
National Center for Protein Sciences, Beijing, China
Short Talk: Chemoproteomic Profiling of Cysteine Redox Networks
Short Talk: Chemoproteomic Profiling of Cysteine Redox Networks
Nils Kurzawa,
European Molecular Biology Laboratory, Germany
Short Talk: Robust Statistical Inference of Small Molecule-Protein Interactions from 2D Thermal Proteome Profiles
Short Talk: Robust Statistical Inference of Small Molecule-Protein Interactions from 2D Thermal Proteome Profiles
Ireshyn S. Govender,
Council for Scientific and Industrial Research, South Africa
Short Talk: Novel Urinary Proteome Profiling Methods and its Application in Biomarker Discovery for Tenofovir-Induced Kidney Injury
Short Talk: Novel Urinary Proteome Profiling Methods and its Application in Biomarker Discovery for Tenofovir-Induced Kidney Injury
17:00—19:00
Complexes and Networks
Proteomics networks and drug discovery
*
Mathias Uhlen,
KTH Royal Inst of Technology, Sweden
Rudolf H. Aebersold,
Institute of Molecular Systems Biology, ETH Zürich, Switzerland
Mass Spectrometric Exploration of the Proteotype
Mass Spectrometric Exploration of the Proteotype
Anne-Claude Gingras,
Lunenfeld-Tanenbaum Research Institute, Canada
A Proteomics View of mTOR Signaling in Humans
A Proteomics View of mTOR Signaling in Humans
Ileana M. Cristea,
Princeton University, USA
Deciphering the Complexity of Viral Infection using Proteomics
Deciphering the Complexity of Viral Infection using Proteomics
Evgenia Shishkova,
University of Wisconsin-Madison, USA
Short Talk: Multi-Omic Profiling of a Large CRISPR Knockout Collection Elucidates Functions of Uncharacterized Mitochondrial Proteins and their Role in Human Disease
Short Talk: Multi-Omic Profiling of a Large CRISPR Knockout Collection Elucidates Functions of Uncharacterized Mitochondrial Proteins and their Role in Human Disease
Alicia Lundby,
University of Copenhagen, Denmark
Short Talk: Deciphering Cardiac Disease Associated Ion Channel Networks by Quantitative Proteomics
Short Talk: Deciphering Cardiac Disease Associated Ion Channel Networks by Quantitative Proteomics
08:30—11:45
Cancer and Other Diseases
Proteomics in disease
*
Judith A. Steen,
Boston Children's Hospital, Harvard Medical Center, USA
Tamar Geiger,
Tel Aviv University, Israel
Unraveling Breast Cancer Heterogeneity through MS-Based Microproteomics, from Whole Tumor Analysis towards Single Cell Single Cell Proteomics
Unraveling Breast Cancer Heterogeneity through MS-Based Microproteomics, from Whole Tumor Analysis towards Single Cell Single Cell Proteomics
Marie Classon,
, USA
Epigenetics/Resistant Cancer
Epigenetics/Resistant Cancer
Coffee Break
Anthony W. Purcell,
Monash University, Australia
Diversification of Tumour Antigen Presentation through Unexpected Proteolysis
Diversification of Tumour Antigen Presentation through Unexpected Proteolysis
Nevan J. Krogan,
University of California, San Francisco, USA
Using Systems Approaches to Understand the Mechanism of Disease
Using Systems Approaches to Understand the Mechanism of Disease
Lukas Käll,
KTH - Royal Institute of Technology, Sweden
Short Talk: A Combined Identification and Quantification Error Model of Label-Free Protein Quantification
Short Talk: A Combined Identification and Quantification Error Model of Label-Free Protein Quantification
Alberto Santos,
Novo Nordisk Foundation Center for Protein Research, Denmark
Short Talk: Graph-Centric Knowledge Mining of Clinical Proteomics Data
Short Talk: Graph-Centric Knowledge Mining of Clinical Proteomics Data
Richard Scheltema,
Utrecht University, Netherlands
Short Talk: Uncovering the Molecular Architecture of Human Fibrin Clots by Cross-Linking Mass Spectrometry
Short Talk: Uncovering the Molecular Architecture of Human Fibrin Clots by Cross-Linking Mass Spectrometry
12:00—14:30
SciLifeLab Lunch Seminar: Proteomics and its Application to Translational and Precision Medicine (Must Register in Advance)
Register here to secure your lunch. There will also be an opportunity to register for the seminar on site at Clarion Hotel Sign, however we will not be able to offer you lunch.
More information about the program and registration: https://www.scilifelab.se/events/keystone-lunch-seminar-proteomics-and-its-application-to-translational-and-precision-medicine/
More information about the program and registration: https://www.scilifelab.se/events/keystone-lunch-seminar-proteomics-and-its-application-to-translational-and-precision-medicine/
17:00—19:00
Neurodegenerative and Immunological Diseases
*
Tamar Geiger,
Tel Aviv University, Israel
Judith A. Steen,
Boston Children's Hospital, Harvard Medical Center, USA
Large Scale Proteome Mapping of Brain Tissue from Neurodegenerative Diseases Informs Mechanism
Large Scale Proteome Mapping of Brain Tissue from Neurodegenerative Diseases Informs Mechanism
Vishva M. Dixit,
Genentech, Inc., USA
Ubiquitin Mediated Regulation of Transcription Factor Stability
Ubiquitin Mediated Regulation of Transcription Factor Stability
Paola Picotti,
ETH Zürich, Switzerland
Proteomes in 3D
Proteomes in 3D
Alessandro Ori,
Leibniz Institute on Aging, Germany
Short Talk: Comprehensive Characterization of Protein Abundance, Stability and Aggregation during Vertebrate Brain Aging
Short Talk: Comprehensive Characterization of Protein Abundance, Stability and Aggregation during Vertebrate Brain Aging
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Biomarkers and Patient Stratification
Integrative Omics for prevention and personalized treatment
*
Albert J.R. Heck,
Utrecht University, Netherlands
Protein Assemblies Investigated by Native and Top-Down Mass Spectrometry
Protein Assemblies Investigated by Native and Top-Down Mass Spectrometry
N. Leigh Anderson,
SISCAPA Assay Technologies, Inc., USA
Biomarker Changes in Time: High-Precision Measurement of Protein Panels in Longitudinal Dried Blood Spots
Biomarker Changes in Time: High-Precision Measurement of Protein Panels in Longitudinal Dried Blood Spots
Coffee Break
Andy N. Hoofnagle,
University of Washington, USA
Clinical Proteomics for Biomarker Discovery
Clinical Proteomics for Biomarker Discovery
Matthias Mann,
Max Planck Institute of Biochemistry, Germany
Plasma Proteomics Profiling as a Universal Phenotyping Approach in Humans
Plasma Proteomics Profiling as a Universal Phenotyping Approach in Humans
Lovisa Aakesson,
KTH - Royal Institute of Technology, Sweden
Short Talk: Large-Scale Mapping of the Human Nucleolar Proteome
Short Talk: Large-Scale Mapping of the Human Nucleolar Proteome
Joseph E. Aslan,
Oregon Health & Science University, USA
Short Talk: Quantitative Phosphoproteomic Profiling and Causality Pathway Mapping the Platelet Response to Vascular Injury
Short Talk: Quantitative Phosphoproteomic Profiling and Causality Pathway Mapping the Platelet Response to Vascular Injury
Henrik J. Johansson,
Karolinska Institutet, Sweden
Short Talk: Breast Cancer Quantitative Proteome and Proteogenomic Landscape
Short Talk: Breast Cancer Quantitative Proteome and Proteogenomic Landscape
15:00—16:30
Workshop: Precision Medicine from Proteomics
*
Michael P. Snyder,
Stanford University School of Medicine, USA
Roman Fischer,
Oxford University, UK
Multi-Omic Prognostic Signatures in Esophageal Cancer Immunotherapy – A Precision Analysis
Multi-Omic Prognostic Signatures in Esophageal Cancer Immunotherapy – A Precision Analysis
Mariya Mardamshina,
Tel Aviv University, Israel
Topological-Proteomics of Breast Cancer Intra-Tumor Heterogeneity Reveals Diversity within Single Tumors
Topological-Proteomics of Breast Cancer Intra-Tumor Heterogeneity Reveals Diversity within Single Tumors
Lili Niu,
University of Copenhagen, Denmark
Plasma Proteome Profiling Discovers Novel Proteins Associated with Non-Alcoholic Fatty Liver Disease
Plasma Proteome Profiling Discovers Novel Proteins Associated with Non-Alcoholic Fatty Liver Disease
Jing Zhu,
Utrecht University, Netherlands
Personalized Human Milk Proteomics Profiling Reveals Early Signatures of Immunogenic responses
Personalized Human Milk Proteomics Profiling Reveals Early Signatures of Immunogenic responses
Maria Reinecke,
Technische Universität München, Germany
Systematic Discovery of the Targets of 1,000 Kinase Inhibitors
Systematic Discovery of the Targets of 1,000 Kinase Inhibitors
Jochen M. Schwenk,
KTH - Royal Institute of Technology, Sweden
Insights From Profiling Human Plasma Proteomes
Insights From Profiling Human Plasma Proteomes
17:00—18:45
Integrative Omics for Prevention and Personalized Treatment
*
Emma K. Lundberg,
SciLifeLab Stockholm and School of Biotechnology, KTH, Sweden
Mathias Uhlen,
KTH Royal Inst of Technology, Sweden
The Human Protein Atlas – Implications for Human Biology, Drug Development and Precision Medicine
The Human Protein Atlas – Implications for Human Biology, Drug Development and Precision Medicine
Michael P. Snyder,
Stanford University School of Medicine, USA
Big Data and Health
Big Data and Health
Mara Monetti,
Pfizer, USA
Expression of PNPLA3 I148M Variant Alters Lipid Droplet Proteome
Expression of PNPLA3 I148M Variant Alters Lipid Droplet Proteome
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
